We learn what the findings could mean for fighting cancer ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks. With competition rising to the company’s cancer ...
Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results